Dong-A drooling over future profits

Published: 2012-02-20 07:00:00

Updated: 2012-02-20 07:00:00

The imminent additional reclassification of 20 over-the-counter (OTC) drugs as “quasi-drugs,” is seen as a much needed move for the industry, but not everyone is going to benefit from it.

A parliamentary health subcommittee on Monday passed a bill to permit the sale of certain drugs at 24-hour...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK